• Intratumoral (IT) treatment with CF33-hNIS-anti-PD-L1 is safe and well-tolerated at dose levels 1 through 3. IMUGENE LIMITED ACN 009 179 551 3
• CF33-hNIS-anti-PD-L1 IT injection induces tumor infiltration of CD4+ and CD8+ Tcells which are critical immune cells signalling localised immune activation connected to CF33-hNIS-anti-PD-L1 injection.
• Significant upregulation of PD-L1 within the tumor microenvironment (TME) further suggests immune activation by CF33-hNIS-anti-PD-L1, an important precursor for immune clearance of tumors.
• SPECT imaging after treatment with CF33-hNIS-anti-PD-L1 showed enhancement at injected lesions in 75% of patients, suggesting local viral replication and hNIS expression. This shows successful tracking of viral replication using non-invasive imaging studies.
Is it time to insert the rocket emojis? Please lord have mercy on our SP and let this be the bottom and the start of a new upward trajectory! GLTAH
IMU Price at posting:
4.1¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Please lord have mercy on our SP and let this be the bottom and the start of a new upward trajectory! GLTAH
(20min delay)